Kushibiki Motoi, Yamada Masahiro, Oikawa Koichi, Tomita Hirofumi, Osanai Tomohiro, Okumura Ken
The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, 036-8562, Japan.
Eur J Pharmacol. 2007 Oct 31;572(2-3):182-8. doi: 10.1016/j.ejphar.2007.06.017. Epub 2007 Jun 27.
Aldosterone is involved in many cardiovascular diseases with increased oxidative stress. Aldosterone-induced cardiac fibrosis is abolished by blockade of angiotensin II Type-1 (AT1) receptor. Recently, non-genomic vasoconstrictor effects of aldosterone were reported in various vascular beds. We tested the hypothesis that aldosterone stimulates angiotensin AT1 receptor, and causes vasoconstriction by increasing oxidative stress in coronary microcirculation. Coronary arterioles (60-120 microm) were isolated from spontaneously hypertensive rats (SHR) and control Wistar Kyoto (WKY) rats, aged 23-26 weeks. They were cannulated, and pressurized at 60 cm H2O. Effect of aldosterone (10(-15) to 10(-6) M) on coronary arteriolar diameter was examined. Aldosterone rapidly and dose-dependently decreased coronary arteriolar diameter in WKY rats and SHR (diameter changes, 8.4+/-0.7% vs 13.9+/-0.8%, P<0.05). Aldosterone-induced vasoconstriction was enhanced by 1.6-folds in SHR compared to WKY rats (P<0.05). Mineralocorticoid receptor antagonist spironolactone (10(-6) M) did not influence aldosterone-induced vasoconstriction. Selective angiotensin AT1 receptor blocker valsartan (10(-4) M) or candesartan (10(-7) M) abolished aldosterone-induced vasoconstriction. Similarly, superoxide dismutase (SOD, 300 U/ml), and NADPH oxidase inhibitor apocynin (10(-4) M) abolished it. Moreover, the vasoconstrictor effect of aldosterone disappeared in denuded vessels. Real-time quantitative RT-PCR revealed that angiotensin AT1 receptor mRNA level in coronary arterioles of SHR was upregulated by 1.5-folds compared to that in WKY rats (P<0.05). Aldosterone causes vasoconstriction in coronary arterioles, and this vasoconstrictor effect is enhanced by genetically defined hypertension. Aldosterone-induced vasoconstriction is mediated by angiotensin AT1 receptor presumably via oxidative stress.
醛固酮与许多伴有氧化应激增加的心血管疾病有关。通过阻断血管紧张素II 1型(AT1)受体可消除醛固酮诱导的心脏纤维化。最近,醛固酮的非基因组血管收缩作用在各种血管床中都有报道。我们检验了这样一个假设:醛固酮刺激血管紧张素AT1受体,并通过增加冠状动脉微循环中的氧化应激导致血管收缩。从23至26周龄的自发性高血压大鼠(SHR)和对照Wistar Kyoto(WKY)大鼠中分离出冠状动脉小动脉(60 - 120微米)。将它们插管,并在60 cm H2O压力下加压。检测醛固酮(10^(-15)至10^(-6) M)对冠状动脉小动脉直径的影响。醛固酮在WKY大鼠和SHR中迅速且剂量依赖性地减小冠状动脉小动脉直径(直径变化,8.4±0.7%对13.9±0.8%,P<0.05)。与WKY大鼠相比,SHR中醛固酮诱导的血管收缩增强了1.6倍(P<0.05)。盐皮质激素受体拮抗剂螺内酯(10^(-6) M)不影响醛固酮诱导的血管收缩。选择性血管紧张素AT1受体阻滞剂缬沙坦(10^(-4) M)或坎地沙坦(10^(-7) M)可消除醛固酮诱导的血管收缩。同样,超氧化物歧化酶(SOD,300 U/ml)和NADPH氧化酶抑制剂阿朴吗啡(10^(-4) M)也可消除该作用。此外,醛固酮的血管收缩作用在去内皮的血管中消失。实时定量RT-PCR显示,与WKY大鼠相比,SHR冠状动脉小动脉中血管紧张素AT1受体mRNA水平上调了1.5倍(P<0.05)。醛固酮导致冠状动脉小动脉血管收缩,并且这种血管收缩作用在遗传性高血压中增强。醛固酮诱导的血管收缩可能通过氧化应激由血管紧张素AT1受体介导。